DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Fleischer, Thomas, Klajic, Jovana, Aure, Miriam Ragle, Louhimo, Riku, Pladsen, Arne V., Ottestad, Lars, Touleimat, Nizar, Laakso, Marko, Halvorsen, Ann Rita, Alnæs, Grethe I. Grenaker, Riis, Margit L.H., Helland, Åslaug, Hautaniemi, Sampsa, Lønning, Per Eystein, Naume, Bjørn, Børresen-Dale, Anne-Lise, Tost, Jörg, Kristensen, Vessela N.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352035/
https://ncbi.nlm.nih.gov/pubmed/27911866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13718
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items